Andrew Cittadine is COO at Monopar Therapeutics (MNPR). They have made 5 open-market trades across 1 company since 2022, most recently 2026-09-30.
CIK 0001863624
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
5 open-market purchases totalling $150K since 2022, never a sale. Across 5 scored buys the stock is down 3.4% at ninety days, and 7.8 points behind the S&P over the same stretch.
5 scored purchases · one row per filing · discretionary only
| Ticker | Shares | Value |
|---|---|---|
| MNPR | 58,054 | $4.0M |
Shares reported on the most recent Form 4, priced at the 2026-10-02 close.
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 40% | 20% | 40% |
| Avg Move | +3.4% | -6.3% | -3.4% |
| Alpha | +2.1% | -8.0% | -7.8% |
| Scored | 5 | 5 | 5 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| MNPR | BUY | 2024-06-18 | 2024-06-21 | $0.78 | $25K | -1.2% | -10.8% | +26.4% |
| MNPR | BUY | 2024-06-13 | 2024-06-17 | $0.91 | $33K | -18.9% | -21.1% | -6.9% |
| MNPR | BUY | 2024-06-03 | 2024-06-05 | $0.77 | $18K | +4.9% | -12.2% | -42.2% |
| MNPR | BUY | 2024-05-29 | 2024-05-31 | $0.64 | $23K | +45.5% | +20.6% | -22.9% |
| MNPR | BUY | 2022-11-14 | 2022-11-16 | $3.09 | $50K | -13.3% | -8.0% | +28.7% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.